Mobile-enhanced Group CBT for Adolescents at Risk Severe Mood Disorders

a study on Mood Disorders

Summary

Eligibility
for people ages 13-17 (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Marc J. Weintraub, PhD (ucla)

Description

Summary

Although cognitive-behavioral therapy (CBT) has shown efficacy in reducing symptoms and rates of mood relapse in adolescents at high risk for severe mood disorders (SMD; i.e., bipolar I/II disorder and recurrent or unremitting major depression), a significant limitation to the CBT's efficacy is the low rate of participant adherence to the prescribed between-session homework tasks. Mobile health applications have the potential to improve adherence to and acceptance of treatment through embedded treatment content, skill-practice, thought and symptom monitoring, all of which are facilitated by reward contingencies and notifications. This study examines whether a mobile application-enhanced CBT can improve participant adherence and treatment acceptance for adolescents at high risk for SMD.

Official Title

Mobile-enhanced Transdiagnostic Group Treatment for Adolescents at Risk for Severe Mood Disorders

Keywords

Adolescents, Mood Disorders, cognitive behavioral therapy (CBT), mobile health (mHealth), Group treatment, Cognitive behavioral therapy (CBT)_no app

Eligibility

You can join if…

Open to people ages 13-17

  1. Meet DSM-5 criteria for at least one past major depressive disorder, persistent depressive disorder, or unspecified bipolar disorder
  2. Be 13-17 years old
  3. English speaking and able to complete written questionnaires
  4. Ability to attend pre-determined group session time(s)
  5. Access to a smartphone to engage with the study app
  6. Medication usage is acceptable, but not required

You CAN'T join if...

  1. Regular use or current abuse of a psychoactive drug
  2. Evidence of behavioral problems that are thought to interfere with group treatment
  3. Suicidality that requires more intensive treatment
  4. Meeting DSM 5 criteria for bipolar I or II disorder, a psychotic disorder, or significant psychiatric symptoms (e.g., self-injurious behavior) that require more intensive treatment
  5. Concurrent participation in cognitive-behavioral therapy
  6. Inability to travel to study sessions and assessments

Location

  • UCLA Semel Institute accepting new patients
    Los Angeles California 90095-8353 United States

Lead Scientist at University of California Health

  • Marc J. Weintraub, PhD (ucla)
    Hs Assistant Clinical Professor, Psychiatry and Biobehavioral Sciences, Medicine. Authored (or co-authored) 38 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT04887155
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated